Fibrinolysis is a process that prevents thrombus blood clots from growing and becoming problematic. ref name Medline Dugdale, David et al. http www.nlm.nih.gov medlineplus ency article 000577.htm Primary or secondary fibrinolysis , Medline Plus. Retrieved 7 August 2011. ref This process has two types primary fibrinolysis and secondary fibrinolysis. The primary type is a normal body process, whereas secondary fibrinolysis is the breakdown of clots due to a medicine, a medical disorder, or some other cause. ref name Medline In fibrinolysis, a fibrin clot, the product of coagulation , is broken down. ref name pmid15842654 cite journal author Cesarman Maus G, Hajjar KA title Molecular mechanisms of fibrinolysis journal British journal of haematology volume 129 issue 3 pages 307 21 year 2005 month May pmid 15842654 doi 10.1111 j.1365 2141.2005.05444.x ref Its main enzyme plasmin cuts the fibrin ... protease s or by the kidney and liver . Physiology Image Fibrinolysis.png right 360px thumb Fibrinolysis ... fibrinolysis to occur. t PA is released into the blood very slowly by the damaged endothelium ... activity is also reduced by thrombin activatable fibrinolysis inhibitor TAFI , which modifies ... in a person that has active fibrinolysis. FDPs, and a specific FDP, the D dimer , can be measured using antibody antigen technology. This is more specific than the TCT, and confirms that fibrinolysis ... fibrinolysis is assessed by comparing the TEM profile in the absence or presence of the fibrinolysis inhibitor aprotinin . Clinically, the TEM is useful for near real time measurement of activated fibrinolysis ... patients. Br J Anaesthesia 2008 100 792 7 ref Testing of overall fibrinolysis can be measured by a euglobulin lysis time ELT assay. The ELT measures fibrinolysis by clotting the euglobulin fraction ... states. However, acquired disturbance of fibrinolysis Hyperfibrinolysis , is not uncommon. Many trauma ... as inhibitors of fibrinolysis. Their application may be beneficial in patients with hyperfibrinolysis ... more details
Fibrinolysis syndrome also known as Defibrinating syndrome, and Hypofibrinogenemia is characterized by an acute hemorrhagic state brought about by inability of the blood to clot, with massive hemorrhages into the skin producing blackish, purplish swellings and sloughing. ref name Andrews cite book author James, William D. Berger, Timothy G. et al. title Andrews Diseases of the Skin clinical Dermatology publisher Saunders Elsevier location year 2006 pages isbn 0 7216 2921 0 oclc doi accessdate ref rp 826 See also Skin lesion References reflist Cutaneous condition stub Category Vascular related cutaneous conditions ... more details
Unreferenced stub auto yes date December 2009 Image Fibrinolysis.png thumb 400px Fibrinolysis A plasminogen activator is a serine protease which converts plasminogen to plasmin, thus promoting fibrinolysis . Types include Tissue plasminogen activator Urokinase It is inhibited by plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 . Serine endopeptidases Antithrombotics Category Hematology DEFAULTSORT Plasminogen Activator blood drug stub pt Ativador do plasminog nio ... more details
The euglobulin lysis time ELT is a test that measures overall fibrinolysis . The test is performed by mixing citrated platelet poor Blood plasma plasma with acid in a glass test tube. This acidification causes the precipitation of certain clotting factors in a complex called the euglobulin fraction . The euglobulin fraction contains the important fibrinolytic factors fibrinogen , PAI 1 , tissue plasminogen activator tPA , plasminogen , and to a lesser extent alpha 2 antiplasmin . The euglobulin fraction also contains factor VIII . After precipitation, the euglobulin fraction is resuspended in a borate solution. Clotting is then activated by the addition of calcium chloride at 37 C. Historically, subsequent amount of fibrinolysis was determined by eye, by observing the clot within the test tube at ten minute intervals until complete lysis had occurred. ref cite paper first E. last Kowalski author E. Kowalski authorlink coauthors M. Kope , S. Niewiarowski title An Evaluation of the Euglobulin Method for the Determination of Fibrinolysis publisher Journal of Clinical Pathology date 1959 ref Newer automated methods have also been developed. These methods use the same principle as the older technique, but use a spectrophotometer to track clot lysis as a function of absorbance optical density . ref cite paper first Amy last Smith author Amy A. Smith coauthors Linda J. Jacobson, Brian I. Miller, William E. Hathaway, Marilyn J. Manco Johnson title A new euglobulin clot lysis assay for global fibrinolysis publisher Thrombosis Research date 2003 ref References Reflist Myeloid blood tests Category Blood tests ... more details
. With various assays, an enhanced fibrinolysis becomes visible in the curve signature TEMogram ... of increased fibrinolysis APTEM compares the TEM in the absence or presence of the fibrinolysis inhibitor aprotinin . In severe cases of activated fibrinolysis, this assay confirms the syndrome already ... more details
The fibrinolysis system is responsible for removing blood clots. Hyperfibrinolysis describes a situation with markedly enhanced fibrinolytic activity, resulting in increased, sometimes catastrophic bleeding. Hyperfibrinolysis can be caused by acquired or congenital reasons. Among the congenital conditions for hyperfibrinolysis, deficiency of alpha 2 antiplasmin ref Carpenter SL, Mathew P. Alpha 2 antiplasmin and its deficiency fibrinolysis out of balance. Haemophilia, 2008 14 1250 4 ref alpha 2 plasmin inhibitor or plasminogen activator inhibitor type 1 PAI 1 ref Takahashi Y, Tanaka T, Minowa H et al. Hereditary partial deficiency of plasminogen activator inhibitor 1 associated with a lifelong bleeding tendency. Int J Hematol 1996 64 61 8 ref are very rare. The affected individuals show a hemophilia like bleeding phenotype. Acquired hyperfibrinolysis is found in liver disease , ref Goerlinger K. Coagulation management during liver transplantation. Haemostaseologie 2006 26 3 Suppl 1 S64 76 ref in patients with severe Physical trauma trauma , ref Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth. 2008 100 792 7 ref during major surgical procedures, ref Vanek T, Jares M, Snircova J, Maly M. Fibrinolysis in coronary artery surgery detection by thrombelastography. Interact Cardiovasc Thorac Surg. 2007 6 700 4 ref and other conditions. A special situation with temporarily enhanced fibrinolysis is thrombolytic therapy with drugs which activate plasminogen , e.g. for use in acute ischemic events or in patients with stroke. In patients with severe trauma, hyperfibrinolysis is associated with poor outcome. ref Sch chl H. Hyperfibrinolysis a prognostic ..., heparin insensitive test performed in the presence of aprotinin fibrinolysis inhibitor, confirms ... fibrinolysis during abdominal aortic surgery. J Cardiothorac Vasc Anesth 2001 15 764 ref This in vitro ... more details
activity. Activated CPB2 reduces fibrinolysis by removing the fibrin C terminus C terminal ... of two thrombin activatable fibrinolysis inhibitor isoforms journal Thromb. Haemost ... encoding human TAFI thrombin activable fibrinolysis inhibitor plasma procarboxypeptidase ... downregulates fibrinolysis . ref name entrez cite web title Entrez Gene CPB2 carboxypeptidase B2 plasma ... ref Image Fibrinolysis.png left framed Fibrinolysis simplified . Blue arrows denote stimulation ... reading citations cite journal author Bouma BN, Mosnier LO title Thrombin activatable fibrinolysis inhibitor TAFI at the interface between coagulation and fibrinolysis. journal Pathophysiol. Haemost ... PE, et al. title Inactivation of active thrombin activable fibrinolysis inhibitor takes place by a process ... journal author Mosnier LO, Lisman T, van den Berg HM, et al. title The defective down regulation of fibrinolysis ... LO, Meijers JC, Bouma BN title The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor TAFI and regulation of fibrinolysis journal Thromb. Haemost. volume 86 issue 4 ... of thrombin activable fibrinolysis inhibitor TAFI do not determine the thrombomodulin dependence ... Association of a single nucleotide polymorphism in CPB2 encoding the thrombin activable fibrinolysis ... al. title Association between plasma thrombin activatable fibrinolysis inhibitor levels and activated ... M title Thrombin activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC ... citations no DEFAULTSORT Thrombin Activatable Fibrinolysis Inhibitor Category Fibrinolytic system ... more details
The liver plays the major role in producing proteins that are secretion secreted into the blood, including major plasma proteins, factors in hemostasis and fibrinolysis , carrier proteins, hormones, prohormones and apolipoproteins Major plasma proteins Human serum albumin , osmolyte and carrier protein fetoprotein , the fetal counterpart of serum albumin Soluble plasma fibronectin , forming a blood clot that stops bleeding C reactive protein , opsonin on microbes ref name Immunology182 Lippincott s Illustrated Reviews Immunology. Paperback 384 pages. Publisher Lippincott Williams & Wilkins July 1, 2007 . Language English. ISBN 978 0781795432. Page 182 ref , acute phase protein Various other globulins Factors in hemostasis and fibrinolysis Stimulators of coagulation All factors in the Coagulation The coagulation cascade coagulation cascade , except factor VIII from endothelium Inhibitors of coagulation , inactivate an enormous variety of proteinases 2 macroglobulin 1 antitrypsin Antithrombin III Protein S Protein C Fibrinolysis , breakdown of fibrin clots plasminogen Inhibitors of fibrinolysis 2 antiplasmin Complement components C1 9, Complement component 3 C3 Carrier proteins Albumin , carries thyroid hormone s and other hormones, particularly fat soluble ones, fatty acids to the liver, unconjugated bilirubin , many medication drugs and calcium Ca sup 2 sup Ceruloplasmin , carries copper Transcortin , carries cortisol , aldosterone and progesterone Haptoglobin , carries free hemoglobin released from erythrocytes Hemopexin , carries free heme released from hemoglobin Insulin like growth factor binding protein IGF binding protein , carries insulin like growth factor 1 Major urinary proteins , carries pheromones in rodents Retinol binding protein , carries retinol Sex hormone binding globulin , carries sex hormones , specifically testosterone and estradiol Thyroxine binding globulin , carries the thyroid hormones thyroxine T4 and 3,5,3 triiodothyronine T3 Transthy ... more details
Image D dimer.png thumb Principles of D dimer testing Fibrin degradation product FDPs , also known as fibrin split products, are components of the blood produced by clot degeneration. ref name pmid7786784 cite journal author Gaffney PJ, Edgell T, Creighton Kempsford LJ, Wheeler S, Tarelli E title Fibrin degradation product FnDP assays analysis of standardization issues and target antigens in plasma journal Br. J. Haematol. volume 90 issue 1 pages 187 94 year 1995 pmid 7786784 doi 10.1111 j.1365 2141.1995.tb03399.x ref These are produced by the action of plasmin on deposited fibrin. The most notable subtype of fibrin degradation products is D dimer . The levels of these FDPs rises after any thrombotic event. It can be used to test for disseminated intravascular coagulation . ref http peir.path.uab.edu coag article 77.shtml Fibrin Fibrinogen Degradation Products Bot generated title ref See also Fibrinolysis References references External links MedlinePlus 003655 medicine stub Category Coagulation system nl Fibrinedegradatieproduct sl Razgradni produkt fibrina ... more details
Infobox scientist name Wolfram Bode image Replace this image male.svg image size 150px caption Wolfram Bode birth date March 8, 1942 birth place Berlin , Germany death date death place residence citizenship nationality Germany ethnicity field Biochemist work institutions Max Planck Institute of Biochemistry alma mater doctoral advisor doctoral students known for Crystallography , Proteases author abbrev bot author abbrev zoo influences influenced prizes footnotes signature Wolfram Bode born March 8, 1942 is a Germany German biochemist . Biography Born in Berlin , Bode was educated in chemistry and biochemistry at the University of G ttingen , the University of T bingen and the University of Munich as a fellow of the Studienstiftung des deutschen Volkes . He obtained his Ph.D. in 1971 at the University of Munich for studies of the bacterial flagellum . Since 1972 he is working at the Max Planck Institute of Biochemistry in Martinsried . Bode is associate professor at the University of Munich. Career During his graduate studies Bode was using x ray scattering . After his Ph.D. he then joined the lab of Robert Huber to work with x ray crystallography. In 1975 Bode published the structure of trypsin , which was among the first protease structures that could be solved. His following work on the structure and function of proteins has contributed significantly to the understanding of several important biological processes, especially coagulation , fibrinolysis and photosynthesis . External links http www.biochem.mpg.de faessler rg bode index.html Wolfram Bode faculty page at the Max Planck Institute of Biochemistry Persondata Metadata see Wikipedia Persondata . NAME Bode, Wolfram ALTERNATIVE NAMES SHORT DESCRIPTION DATE OF BIRTH March 8, 1942 PLACE OF BIRTH Berlin , Germany DATE OF DEATH PLACE OF DEATH DEFAULTSORT Bode, Wolfram Category 1942 births Category Living people Category People from Berlin Category German biochemists Category Studienstiftung alumni Category Ludwig ... more details
conditions, the body is maintained in a finely tuned balance of coagulation and fibrinolysis . The activation ... of coagulation and is also necessary for the breakdown of clots, or fibrinolysis. In DIC, the processes of coagulation and fibrinolysis are dysregulated, and the result is widespread clotting with resultant ... in the release of TF and plasminogen activator inhibitor 1 PAI 1 , which prevents fibrinolysis ..., resulting in fibrinolysis. The breakdown of clots results in excess amounts of FDPs, which ... are dissolved by fibrinolysis . In some situations, infusion with antithrombin may be necessary ... more details
journal author Nielsen VG title Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2 antiplasmin plasmin interactions journal Blood Coagul. Fibrinolysis volume 18 issue ... IY title Fibrinolysis is amplified by converting alpha antiplasmin from a plasmin inhibitor to a substrate ... more details
to form a clot. FXIIIa stabilizes fibrin further by incorporation of the fibrinolysis inhibitors alpha 2 antiplasmin and TAFI thrombin activatable fibrinolysis inhibitor, procarboxypeptidase B , and binding ... L, Bagoly Z, Bereczky Z, Katona E title The involvement of blood coagulation factor XIII in fibrinolysis ..., which stay active and can be released during fibrinolysis. ref name pmid12847561 cite journal ... more details
Image Epoxyeicosatrienoic acid.png thumb right 350px Chemical structure of 14,15 epoxyeicosatrienoic acid. The Epoxyeicosatrienoic acids or EETs are signaling molecules formed by the action of Cytochrome P450 oxidase Cytochrome P450 epoxygenase on 20 carbon essential fatty acid s, such as arachidonic acid , from which it is produced by the enzyme epoxygenase . ref name boron108 cite book author Walter F., PhD. Boron title Medical Physiology A Cellular And Molecular Approaoch publisher Elsevier Saunders year 2003 page 108 isbn 1 4160 2328 3 ref These nonclassic eicosanoid s act as short range hormone s, i.e. they are Autocrine signalling autocrine and Paracrine signalling paracrine mediators of the cardiovascular system and kidney . They produce Vasodilator vasorelaxation as well as anti inflammatory and Fibrinolysis pro fibrinolytic effects. ref cite journal author Spector AA, Fang X, Snyder GD, Weintraub NL journal Prog Lipid Res year 2004 month January volume 43 issue 1 pages 55 90 title Epoxyeicosatrienoic acids EETs metabolism and biochemical function pmid 14636671 doi 10.1016 S0163 7827 03 00049 3 ref EETs are metabolized by the soluble epoxide hydrolase to the corresponding vicinal diol , or dihydroxyeicosatrienoic acids DHETs , which are biologically less active. Biological effects Generally, EETs cause Calcium release from intracellular stores ref name boron108 Increased sodium hydrogen antiporter activity ref name boron108 Increased cell proliferation ref name boron108 Decreased cyclooxygenase activity ref name boron108 Other effects are specific to certain cells or locations EETs are cardioprotective after Myocardial infarction ischemic heart attack and reperfusion. ref cite journal author Nithipatikom K, Moore JM, Isbell MA, Falck JR, Gross GJ title Epoxyeicosatrienoic acids in cardioprotection ischemic versus reperfusion injury journal Am. J. Physiol. Heart Circ. Physiol. volume 291 issue 2 pages H537 42 year 2006 month August pmid 16473964 doi 10.1152 a ... more details
Image D sir Collen 071230.jpg thumb 200px right D sir Collen D sir Collen born 21 June 1943 is a Belgium Belgian physician and chemist . He was born in Sint Truiden , Belgium . Education He graduated as an M.D. at the Katholieke Universiteit Leuven in 1968 and obtained a PhD in chemistry in 1974. Career He started his career as in 1968 1971 as a Resident in Internal Medicine at the University Hospitals of the Katholieke Universiteit Leuven. Since 2002 he has been a professor at the Centre for Molecular en Vascular Biology, and he is also head of the Vlaams Instituut voor Biotechnologie VIB D partement of Transgene Technology and Gene Therapy, K.U.Leuven . Together with professor Billiau he discovered Tissue plasminogen activator tPA in 1979. ref Collen D, Billiau A, Edy J, De Somer P., Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells, Biochim Biophys Acta. 1977 September 29 499 2 194 201 ref ref Collen D, Verstraete M. Systemic thrombolytic therapy of acute myocardial infarction? Circulation. 1983 Aug 68 2 462 465 ref ref Collen D. Human tissue type plasminogen activator from the laboratory to the bedside. Circulation. 1985 Jul 72 1 18 20 ref He is the founder of the Flanders Flemish biotech company Thromb X . Awards 1984 Francqui Prize on Biological and Medical Sciences. 1985 Louis Jeantet Prize for Medicine , together with Luc Montagnier and Michael Berridge . 2005 Interbrew Baillet Latour Health Prize , together with Peter Carmeliet . ref Bloom S., Belgian scientists awarded top honors, J Clin Invest. 2005 May 115 5 1106 7 ref References references External links http www.kuleuven.be cv u0016103.htm D sir Collen Persondata Metadata see Wikipedia Persondata . NAME Collen, Desire ALTERNATIVE NAMES SHORT DESCRIPTION chemist, physician DATE OF BIRTH 21 June 1943 PLACE OF BIRTH DATE OF DEATH PLACE OF DEATH Use dmy dates date February 2011 DEFAULTSORT Collen, Desire Category Belgian academics Category Belgian sc ... more details
Orphan date December 2007 Automatically added by User SoxBot. If this is an error, please contact User Soxred93 Albert Dastre November 7, 1844 October 22, 1917 was a French physiologist born in Paris . He studied and worked under Claude Bernard 1813 1878 and Paul Bert 1830 1886 in Paris , and in 1886 attained the chair of General Physiology at the Sorbonne . In 1904 Dastre became a member of the Acad mie des sciences . One of his better known assistants was Romanian physiologist Nicolae Paulescu 1869 1931 , who was the discoverer of insulin . Albert Dastre specialized in the field of physiological chemistry , and is remembered for his studies of glycosuria and diabetes , as well as his discovery involving the proteolytic properties of blood. In 1893, he noticed a reduction of fibrin during a Venipuncture phlebotomy in dogs, which he attributed to a destruction of fibrin. He called this phenomenon fibrinolysis to describe the dissolution of fibrin and the breakup of blood clots. Dastre also observed fibrin dissolve when mixed with an antiseptic salt solution, and postulated that it was a form of digestion. Among his written works was a philosophic and scientific treatise on life and death titled La Vie et la Mort , and in 1878 79 he published and edited Le ons sur les Ph nom nes de la vie communs aux animaux et aux v g taux , a work composed by his former mentor, Claude Bernard. With his colleague Jean Pierre Morat 1846 1920 , the Dastre Morat Law is derived, which states that constriction of the body s surface blood vessel s is usually accompanied by Vasodilation dilation of vessels of the viscera, and vice versa . References cite book title Laws and Models author Carl W. Hall year 2000 publisher CRC Press isbn 0 8493 2018 6 url http books.google.com books?id EEhpsf6L09gC&pg PA109&lpg PA109&dq 22dastre morat 22 law&source web&ots SxS8SYxh1L&sig EVAXW0mRYUsHuJ4ITPu8gQ4NtfM PPA109,M1 Persondata Metadata see Wikipedia Persondata . NAME Dastre, Albert ALTERNATIVE NAMES ... more details
Infobox disease Name Quebec platelet disorder Image Alt Caption DiseasesDB ICD10 ICD9 ICDO OMIM 601709 MedlinePlus eMedicineSubj eMedicineTopic MeshID GeneReviewsID GeneReviewsName Quebec Platelet Disorder QPD is a rare, autosomal dominant bleeding disorder described in a family from the province of Quebec in Canada ref Hayward CP, Rivard GE, Kane WH, Drouin J, Zheng S, Moore JC, Kelton JG. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996 87 4967 78. ref ref Diamandis M, Veljkovic DK, Maurer Spurej E, Rivard GE, Hayward CPM. Quebec platelet disorder features, pathogenesis and treatment. Blood Coagulation and Fibrinolysis 2008 . 19 2 109 119 ref . Pathophysiology The disorder is characterized by large amounts of the fibrinolytic enzyme urokinase type plasminogen activator u PA in platelets ref name Kahr, 2001 Kahr, 2001 ref . Consequently, stored platelet plasminogen is converted to plasmin , which is thought to play a role in degrading a number of proteins stored in platelet granules ref Sheth, 2003 ref . These proteins include platelet factor V, Von Willebrand factor, fibrinogen, thrombospondin 1, and osteonectin ref name Kahr, 2001 . There is also a quantitative deficiency in the platelet protein multimerin 1 MMRN1 . Furthermore, upon QPD platelet activation, u PA can be released into forming clots and accelerate clot lysis, resulting in delayed onset bleeding 12 24hrs after injury ref Diamandis & Adam, 2006 ref . Presentation Individuals with QPD are at risk for experiencing a number of bleeding symptoms, including joint bleeds, hematuria, and large brusing ref McKay & Haq, 2004 ref . In 2010, the genetic cause of QPD has been determined as a mutation involving an extra copy of the uPA urokinase plasminogen activator gene ref Persons with Quebec platelet disorder have a tandem dupl ... more details
Amyloid purpura is a condition marked by bleeding under the skin purpura in some individuals with amyloidosis . ref name Eder cite journal author Eder L, Bitterman H title Image in clinical medicine. Amyloid purpura journal N. Engl. J. Med. volume 356 issue 23 pages 2406 year 2007 month June pmid 17554122 doi 10.1056 NEJMicm061510 url http content.nejm.org cgi pmidlookup?view short&pmid 17554122 ref Its cause is unknown, but coagulation defects caused by amyloid are thought to contribute. Cause The precise cause of amyloid purpura is unknown, but several mechanisms are thought to contribute. ref name Gamba cite journal author Gamba G, Montani N, Anesi E, et al. title Clotting alterations in primary systemic amyloidosis journal Haematologica volume 85 issue 3 pages 289 92 year 2000 month March pmid 10702818 doi url http www.haematologica.org cgi reprint 85 3 289.pdf ref One may be a decrease in the level of circulating factor X , ref name Gamba a clotting factor necessary for coagulation . The proposed mechanism for this decrease in factor X is that circulating amyloid fibrils bind and inactivate factor X. ref name Gamba Another contributing factor may be enhanced fibrinolysis , ref name Gamba the breakdown of clot s. Endothelium Subendothelial deposits of amyloid may weaken blood vessel s and lead to the extravasation of blood. ref name Gamba ref name emedicine eMedicine med 3363 Amyloidosis, Immunoglobulin Related ref Amyloid deposits in the gastrointestinal tract and liver may also play a role in the development of amyloid purpura. ref name Gamba Distribution Amyloid purpura usually occurs above the nipple line and is found in the webbing of the neck and in the face and eyelids. ref name Eder Epidemiology Amyloid purpura affects a minority of individuals with amyloidosis. ref name Eder For example, purpura is present early in the disease in approximately 15 of patients with primary systemic amyloidosis . ref name Kyle cite journal author Kyle RA, Gertz MA title Pr ... more details
Encyclopedia
top
